(SNN) Smith & Nephew SNATS - Overview
Stock: Orthopaedics, Sports Medicine, Wound Care, Implants, Biologics
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.48% |
| Yield on Cost 5y | 2.00% |
| Yield CAGR 5y | 0.40% |
| Payout Consistency | 95.5% |
| Payout Ratio | 2.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 27.0% |
| Relative Tail Risk | -10.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.26 |
| Alpha | 32.82 |
| Character TTM | |
|---|---|
| Beta | 0.462 |
| Beta Downside | 0.618 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.29% |
| CAGR/Max DD | 0.32 |
Description: SNN Smith & Nephew SNATS January 03, 2026
Smith & Nephew plc (NYSE:SNN) designs, manufactures and markets a broad portfolio of medical-device products across three operating segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The firm serves hospitals and other healthcare providers in the U.K., the United States and globally.
Its Orthopaedics line includes knee and hip implants (including revision-type hip devices), trauma and extremities fixation systems, and other reconstruction solutions. The Sports Medicine & ENT segment supplies minimally invasive joint-repair instruments, arthroscopic visualization equipment, and ENT devices. Advanced Wound Management offers chronic-wound dressings, biologic grafts, negative-pressure therapy (both reusable and single-use), and hydrosurgery platforms.
Key recent metrics: FY 2023 revenue reached approximately **$5.2 billion**, up 7 % YoY, driven primarily by a **10 % growth rate in orthopaedic sales** and a **6 % rise in wound-care revenue**. R&D spending remained steady at **~7 % of sales**, supporting pipeline launches such as a next-generation knee implant that received FDA clearance in Q3 2024. The United States now accounts for roughly **55 % of total revenue**, reflecting the market’s reliance on high-volume joint-replacement procedures.
Sector-level drivers that shape Smith & Nephew’s outlook include an aging global population (projected to add ~30 million new joint-replacement candidates in the next decade), tightening reimbursement policies that favor cost-effective, minimally invasive solutions, and ongoing supply-chain pressures that have heightened the value of single-use, sterilization-free devices. These macro trends underpin the company’s focus on high-margin, technology-enabled product lines.
For a deeper, data-driven assessment of SNN’s valuation and risk profile, you may find the analytical tools on **ValueRay** worth exploring.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 814.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 5.42 > 1.0 |
| NWC/Revenue: 30.20% < 20% (prev 21.13%; Δ 9.06% < -1%) |
| CFO/TA 0.14 > 3% & CFO 1.51b > Net Income 814.6m |
| Net Debt (2.78b) to EBITDA (2.22b): 1.25 < 3 |
| Current Ratio: 3.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (439.9m) vs 12m ago -49.60% < -2% |
| Gross Margin: 69.95% > 18% (prev 0.70%; Δ 6925 % > 0.5%) |
| Asset Turnover: 98.80% > 50% (prev 83.34%; Δ 15.46% > 0%) |
| Interest Coverage Ratio: 4.98 > 6 (EBITDA TTM 2.22b / Interest Expense TTM 254.8m) |
Altman Z'' 5.29
| A: 0.29 (Total Current Assets 4.62b - Total Current Liabilities 1.54b) / Total Assets 10.68b |
| B: 0.48 (Retained Earnings 5.12b / Total Assets 10.68b) |
| C: 0.12 (EBIT TTM 1.27b / Avg Total Assets 10.33b) |
| D: 0.96 (Book Value of Equity 4.96b / Total Liabilities 5.15b) |
| Altman-Z'' Score: 5.29 = AAA |
Beneish M -2.83
| DSRI: 1.14 (Receivables 1.48b/1.06b, Revenue 10.21b/8.32b) |
| GMI: 1.00 (GM 69.95% / 70.14%) |
| AQI: 0.96 (AQ_t 0.43 / AQ_t-1 0.45) |
| SGI: 1.23 (Revenue 10.21b / 8.32b) |
| TATA: -0.06 (NI 814.6m - CFO 1.51b) / TA 10.68b) |
| Beneish M-Score: -2.83 (Cap -4..+1) = A |
What is the price of SNN shares?
Over the past week, the price has changed by +2.34%, over one month by +4.44%, over three months by +5.13% and over the past year by +45.37%.
Is SNN a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SNN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 36.4 | 3.9% |
| Analysts Target Price | 36.4 | 3.9% |
| ValueRay Target Price | 37.8 | 7.7% |
SNN Fundamental Data Overview February 03, 2026
P/E Forward = 12.4378
P/S = 2.4781
P/B = 2.5806
P/EG = 0.6554
Revenue TTM = 10.21b USD
EBIT TTM = 1.27b USD
EBITDA TTM = 2.22b USD
Long Term Debt = 3.15b USD (from longTermDebt, last quarter)
Short Term Debt = 156.9m USD (from shortTermDebt, last quarter)
Debt = 3.45b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.78b USD (from netDebt column, last quarter)
Enterprise Value = 17.51b USD (14.73b + Debt 3.45b - CCE 675.4m)
Interest Coverage Ratio = 4.98 (Ebit TTM 1.27b / Interest Expense TTM 254.8m)
EV/FCF = 19.49x (Enterprise Value 17.51b / FCF TTM 898.3m)
FCF Yield = 5.13% (FCF TTM 898.3m / Enterprise Value 17.51b)
FCF Margin = 8.80% (FCF TTM 898.3m / Revenue TTM 10.21b)
Net Margin = 7.98% (Net Income TTM 814.6m / Revenue TTM 10.21b)
Gross Margin = 69.95% ((Revenue TTM 10.21b - Cost of Revenue TTM 3.07b) / Revenue TTM)
Gross Margin QoQ = 70.62% (prev 69.46%)
Tobins Q-Ratio = 1.64 (Enterprise Value 17.51b / Total Assets 10.68b)
Interest Expense / Debt = 2.37% (Interest Expense 81.7m / Debt 3.45b)
Taxrate = 19.06% (69.6m / 365.3m)
NOPAT = 1.03b (EBIT 1.27b * (1 - 19.06%))
Current Ratio = 3.00 (Total Current Assets 4.62b / Total Current Liabilities 1.54b)
Debt / Equity = 0.62 (Debt 3.45b / totalStockholderEquity, last quarter 5.53b)
Debt / EBITDA = 1.25 (Net Debt 2.78b / EBITDA 2.22b)
Debt / FCF = 3.09 (Net Debt 2.78b / FCF TTM 898.3m)
Total Stockholder Equity = 5.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.88% (Net Income 814.6m / Total Assets 10.68b)
RoE = 15.37% (Net Income TTM 814.6m / Total Stockholder Equity 5.30b)
RoCE = 15.01% (EBIT 1.27b / Capital Employed (Equity 5.30b + L.T.Debt 3.15b))
RoIC = 11.92% (NOPAT 1.03b / Invested Capital 8.62b)
WACC = 6.54% (E(14.73b)/V(18.18b) * Re(7.62%) + D(3.45b)/V(18.18b) * Rd(2.37%) * (1-Tc(0.19)))
Discount Rate = 7.62% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -29.01%
[DCF Debug] Terminal Value 84.49% ; FCFF base≈658.4m ; Y1≈705.2m ; Y5≈856.6m
Fair Price DCF = 42.69 (EV 20.90b - Net Debt 2.78b = Equity 18.12b / Shares 424.4m; r=6.54% [WACC]; 5y FCF grow 7.97% → 2.90% )
EPS Correlation: 4.50 | EPS CAGR: -73.48% | SUE: 0.0 | # QB: 0
Revenue Correlation: 39.77 | Revenue CAGR: 24.86% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=1.81 | Chg30d=+0.004 | Revisions Net=+1 | Growth EPS=+12.0% | Growth Revenue=+5.5%